Document is current
Any future updates will be listed below
-
Authors
Zou, Yilong https://orcid.org/0000-0001-8198-6067
Henry, Whitney S.
Ricq, Emily L.
Graham, Emily T. https://orcid.org/0000-0001-6696-4564
Phadnis, Vaishnavi V. https://orcid.org/0000-0001-8452-8512
Maretich, Pema
Paradkar, Sateja
Boehnke, Natalie
Deik, Amy A.
Reinhardt, Ferenc
Eaton, John K. https://orcid.org/0000-0003-4633-5546
Ferguson, Bryan
Wang, Wenyu
Fairman, Joshua
Keys, Heather R. https://orcid.org/0000-0003-1371-2288
Dančík, Vlado
Clish, Clary B. https://orcid.org/0000-0001-8259-9245
Clemons, Paul A. https://orcid.org/0000-0002-1800-5112
Hammond, Paula T. https://orcid.org/0000-0002-9835-192X
Boyer, Laurie A.
Weinberg, Robert A. https://orcid.org/0000-0002-0895-3557
Schreiber, Stuart L. https://orcid.org/0000-0003-1922-7558
- License Information
-
More Information
Article History
Received: 26 November 2019
Accepted: 24 June 2020
First Online: 16 September 2020
Competing interests
: S.L.S. serves on the Board of Directors of the Genomics Institute of the Novartis Research Foundation (‘GNF’); is a shareholder and serves on the Board of Directors of Jnana Therapeutics; is a shareholder of Forma Therapeutics; is a shareholder and advises Kojin Therapeutics, Kisbee Therapeutics, Decibel Therapeutics and Eikonizo Therapeutics; serves on the Scientific Advisory Boards of Eisai Co., Ltd., Ono Pharma Foundation, Exo Therapeutics and F-Prime Capital Partners; and is a Novartis Faculty Scholar. Kojin Therapeutics in particular explores the medical potential of cell plasticity related to ferroptosis. P.A.C. is an advisor to Pfizer, Inc. The other authors declare no conflict of interest relevant to this study.
